Icodextrin improves the fluid status of peritoneal dialysis patients: Results of a double-blind randomized controlled trial
(2003) In Journal of the American Society of Nephrology 14(9). p.2338-2344- Abstract
- Worsening fluid balance results in reduced technique and patient survival in peritoneal dialysis. Under these conditions, the glucose polymer icodextrin is known to enhance ultrafiltration in the long dwell. A multicenter, randomized, double-blind, controlled trial was undertaken to compare icodextrin versus 2.27% glucose to establish whether icodextrin improves fluid status. Fifty patients with urine output <750 ml/d, high solute transport, and either treated hypertension or untreated BP >140/90 mmHg, or a requirement for the equivalent of all 2.27% glucose exchanges, were randomized 1: 1 and evaluated at 1, 3, and 6 mo. Members of the icodextrin group lost weight, whereas the control group gained weight. Similar differences in... (More)
- Worsening fluid balance results in reduced technique and patient survival in peritoneal dialysis. Under these conditions, the glucose polymer icodextrin is known to enhance ultrafiltration in the long dwell. A multicenter, randomized, double-blind, controlled trial was undertaken to compare icodextrin versus 2.27% glucose to establish whether icodextrin improves fluid status. Fifty patients with urine output <750 ml/d, high solute transport, and either treated hypertension or untreated BP >140/90 mmHg, or a requirement for the equivalent of all 2.27% glucose exchanges, were randomized 1: 1 and evaluated at 1, 3, and 6 mo. Members of the icodextrin group lost weight, whereas the control group gained weight. Similar differences in total body water were observed, largely explained by reduced extracellular fluid volume in those receiving icodextrin, who also achieved better ultrafiltration and total sodium losses at 3 mo (P < 0.05) and had better maintenance of urine volume at 6 mo (P = 0.039). In patients fulfilling the study's inclusion criteria, the use of icodextrin, when compared with 2.27% glucose, in the long exchange improves fluid removal and status in peritoneal dialysis. This effect is apparent within I mo of commencement and was sustained for 6 mo without harmful effects on residual renal function. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/302199
- author
- organization
- publishing date
- 2003
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of the American Society of Nephrology
- volume
- 14
- issue
- 9
- pages
- 2338 - 2344
- publisher
- American Society of Nephrology
- external identifiers
-
- wos:000185025500015
- pmid:12937311
- scopus:10744222476
- ISSN
- 1046-6673
- DOI
- 10.1097/01.ASN.0000083904.12234.27
- language
- English
- LU publication?
- yes
- id
- 4055c5e0-3b00-419c-b439-82b9747ff601 (old id 302199)
- alternative location
- http://jasn.asnjournals.org/cgi/content/abstract/14/9/2338
- date added to LUP
- 2016-04-01 16:08:54
- date last changed
- 2022-04-15 02:27:23
@article{4055c5e0-3b00-419c-b439-82b9747ff601, abstract = {{Worsening fluid balance results in reduced technique and patient survival in peritoneal dialysis. Under these conditions, the glucose polymer icodextrin is known to enhance ultrafiltration in the long dwell. A multicenter, randomized, double-blind, controlled trial was undertaken to compare icodextrin versus 2.27% glucose to establish whether icodextrin improves fluid status. Fifty patients with urine output <750 ml/d, high solute transport, and either treated hypertension or untreated BP >140/90 mmHg, or a requirement for the equivalent of all 2.27% glucose exchanges, were randomized 1: 1 and evaluated at 1, 3, and 6 mo. Members of the icodextrin group lost weight, whereas the control group gained weight. Similar differences in total body water were observed, largely explained by reduced extracellular fluid volume in those receiving icodextrin, who also achieved better ultrafiltration and total sodium losses at 3 mo (P < 0.05) and had better maintenance of urine volume at 6 mo (P = 0.039). In patients fulfilling the study's inclusion criteria, the use of icodextrin, when compared with 2.27% glucose, in the long exchange improves fluid removal and status in peritoneal dialysis. This effect is apparent within I mo of commencement and was sustained for 6 mo without harmful effects on residual renal function.}}, author = {{Davies, SJ and Woodrow, G and Donovan, K and Plum, J and Williams, P and Johansson, AC and Bosselmann, HP and Heimburger, O and Simonsen, Ole and Davenport, A and Tranaeus, A and Divino, JC}}, issn = {{1046-6673}}, language = {{eng}}, number = {{9}}, pages = {{2338--2344}}, publisher = {{American Society of Nephrology}}, series = {{Journal of the American Society of Nephrology}}, title = {{Icodextrin improves the fluid status of peritoneal dialysis patients: Results of a double-blind randomized controlled trial}}, url = {{http://dx.doi.org/10.1097/01.ASN.0000083904.12234.27}}, doi = {{10.1097/01.ASN.0000083904.12234.27}}, volume = {{14}}, year = {{2003}}, }